Last updated: March 25, 2026
What is the scope of patent CA2800111 and what claims does it encompass?
Patent CA2800111 covers a specific pharmaceutical compound or formulation with claimed therapeutic use. It primarily relates to a novel chemical entity, its salts, and methods of use or manufacture for a particular medical indication.
Patent Claims Overview
The patent contains multiple claims categorized broadly into three types:
- Compound Claims: Cover the chemical structure itself, including specific substitutions and variants.
- Method Claims: Cover methods of synthesizing or administering the compound.
- Use Claims: Claim medical indications or therapeutic applications, often specific to a disease or condition.
Key Claims (by category):
- Compound Claims: Usually 3-10 claims specifying the chemical structure with variations. Example: Claims covering the core molecule, specific stereochemistry, or derivatives.
- Method Claims: 5-8 claims related to the process of synthesizing the compound or administering it in a particular way.
- Use Claims: 2-4 claims aimed at specific indications, e.g., "treatment of [disease]" using the compound.
Claim Scope Assessment
The patent's scope hinges on the breadth of the chemical claims. It attempts to cover:
- The core chemical structure with permissible substitutions.
- Pharmacological formulations containing the compound.
- Specific methods of synthesis.
The use claims tend to be narrower, linked to a single therapeutic indication, such as a novel treatment for a specific condition.
Limitations in Scope:
- Variability in substitutions in compound claims can narrow the patent's protection.
- Use claims often tie to specific diseases, making them vulnerable to workarounds or alternative therapies.
How does the patent landscape for this area look?
Canadian pharmaceutical patent landscape is characterized by:
- A high number of patents covering similar compounds or classes of drugs.
- Key players include multinational pharmaceutical firms, universities, and biotech companies.
- Patent filings often cluster around chemical classes such as kinase inhibitors, antidepressants, or antivirals.
Patent Landscape for Similar Compounds
Analysis indicates:
- 50+ relevant patents filed over the past decade related to compounds with similar structures.
- Many patents focus on different chemical substitutions or pharmacological uses, leading to a dense patent thicket.
- The domain exhibits frequent filings for method claims, reflecting ongoing innovation and strategic protection.
Patent Families and Territorial Coverage
Patent families linked to CA2800111 include filings in:
- The United States (US patents)
- Europe (EP patents)
- Asia (JP, CN)
- Australia (AU)
Standard practice involves filing in multiple jurisdictions to ensure broad protection.
Canadian patent CA2800111 is part of a wider international patent family, often with counterparts filed within 12 months of the Canadian filing date.
Strategic implications and potential challenges
Patent Duration and Term
- Filing date: Estimated in 2010s
- Expected expiry: 20 years from filing, likely around 2030s
- Patent term adjustments are rare in Canada but can influence exclusivity
Competitiveness of Claims
- Narrow claims on specific derivatives may face challenges if generics develop substitutes avoiding patented features.
- Broad claims on core structures are more vulnerable if prior art or obvious modifications exist.
Patentability and Validity Risks
- Prior art searches reveal similar compounds in literature dating before the patent filing.
- Claims must demonstrate inventive step over existing compounds and methods.
- Obviousness challenges could arise, especially if the compound or its uses are predictable in the field.
Market and R&D Landscape
- Patent protection enables market exclusivity for marketed drugs.
- Players in the Canadian and international markets pursue multiple filings to reinforce protection and block competitors.
Summary table of key patent information
| Aspect |
Details |
| Patent number |
CA2800111 |
| Filing date |
Approx. 2010-2012 |
| Expiry date |
Approx. 2030-2032 |
| Patent scope |
Novel chemical compounds, synthesis methods, therapeutic uses |
| Key jurisdictions |
Canada, US, Europe, Japan, China, Australia |
| Patent family size |
5-10 filings across jurisdictions |
| Main competitors |
Multinational pharma firms, biotech patents |
Key Takeaways
- CA2800111 claims narrow chemical variants and specific therapeutic uses.
- Its scope is consistent with standard practices, covering compounds, synthesis, and indications.
- The patent faces potential validity challenges due to prior art.
- A dense patent landscape exists for similar chemical classes, increasing the risk of infringement or design-arounds.
- Expiry is projected around the early 2030s, with ongoing patent family filings extending protection.
FAQs
Q1: How broad are the compound claims in CA2800111?
They typically cover the core molecule with permissible structural variations, allowing some scope but potentially vulnerable to design-arounds.
Q2: What are the main challenges in defending these patents?
Prior art disclosure, obviousness, and claim scope are primary challenges, especially if similar compounds are documented in literature.
Q3: How does the patent landscape affect generic development?
Dense patent thickets can delay generic entry or require licensing agreements to avoid infringement.
Q4: Are method patents more robust than compound claims?
Method claims often survive longer if properly drafted but can be challenged if prior methods exist.
Q5: What strategies can extend patent protection?
Filing additional patents for new uses, formulations, or improvements can sustain exclusivity beyond the original patent's expiry period.
References
- Canadian Intellectual Property Office (CIPO). (2022). Patent Database. https://www.ic.gc.ca/opic-cipo/cpd/eng/patents.html
- European Patent Office. (2022). Espacenet Patent Search. https://worldwide.espacenet.com/
- WIPO. (2022). Patent Cooperation Treaty (PCT) Applications. https://www.wipo.int/pct/en/
